2 research outputs found
ΠΡΠ΅Π½ΠΊΠ° Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΡΠ΅Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ Π΄Π΅ΡΠ΅ΠΉ ΡΡΠ°ΡΡΠ΅ 1,5 Π»Π΅Ρ ΠΏΡΠΎΡΠΈΠ² Π΄ΠΈΡΡΠ΅ΡΠΈΠΈ, ΠΊΠΎΠΊΠ»ΡΡΠ°, ΡΡΠΎΠ»Π±Π½ΡΠΊΠ°, ΠΏΠΎΠ»ΠΈΠΎΠΌΠΈΠ΅Π»ΠΈΡΠ° ΠΈ Π³Π΅ΠΌΠΎΡΠΈΠ»ΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΡΠΈΠΏΠ° Π Π²Π°ΠΊΡΠΈΠ½ΠΎΠΉ ΠΠ΅Π½ΡΠ°ΠΊΡΠΈΠΌ
Supervision over 200 children in the age of 18β42 months (64 healthy and 136 with allergic displays, defeats CNS, often ill, and also having in the anamnesis of reaction to previous introduction DTP or Infanriks), revaccination with Pentaxim. It is shown, that 77% from them had asymptomatic current, only in 1,5% of cases strong reactions with temperature above 38,6Β°Π‘ were observed. Local reactions were marked at 25,5%, essentially more often at children with an allergy, defeat CNS and often ill, than at healthy (7,8%), but did not one child was not adverse events. The estimation safety vaccines Pentaxim confirms expediency of application as 1 revaccination against perussis, diphtheria, tetanus, poliomyelitis and unitary vaccination against Haemophilus influenzae type B in children are more senior than year with a various state of health.ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ Π·Π° 200 Π΄Π΅ΡΡΠΌΠΈ Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ 18β42 ΠΌΠ΅Ρ. (64 Π·Π΄ΠΎΡΠΎΠ²ΡΠΌΠΈ ΠΈ 136 Ρ Π°Π»Π»Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡΠΌΠΈ, ΡΠ΅Π·ΠΈΠ΄ΡΠ°Π»ΡΠ½ΡΠΌΠΈ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡΠΌΠΈ Π¦ΠΠ‘, ΡΠ°ΡΡΠΎ Π±ΠΎΠ»Π΅ΡΡΠΈΠΌΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΈΠΌΠ΅ΡΡΠΈΠΌΠΈ Π² Π°Π½Π°ΠΌΠ½Π΅Π·Π΅ ΡΠ΅Π°ΠΊΡΠΈΠΈ Π½Π° ΠΏΡΠ΅Π΄ΡΠ΅ΡΡΠ²ΡΡΡΠ΅Π΅ Π²Π²Π΅Π΄Π΅Π½ΠΈΠ΅ ΠΠΠΠ‘ ΠΈ ΠΠ½ΡΠ°Π½ΡΠΈΠΊΡ), ΡΠ΅Π²Π°ΠΊΡΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌΠΈ Π²Π°ΠΊΡΠΈΠ½ΠΎΠΉ ΠΠ΅Π½ΡΠ°ΠΊΡΠΈΠΌ. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ Π² ΠΏΠΎΡΡΠ²Π°ΠΊΡΠΈΠ½Π°Π»ΡΠ½ΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ 77% ΠΈΠΌΠ΅Π»ΠΈ Π±Π΅ΡΡΠΈΠΌΠΏΡΠΎΠΌΠ½ΠΎΠ΅ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅, ΡΠΎΠ»ΡΠΊΠΎ Π² 1,5% ΡΠ»ΡΡΠ°Π΅Π² Π½Π°Π±Π»ΡΠ΄Π°Π»ΠΈΡΡ ΡΠΈΠ»ΡΠ½ΡΠ΅ ΡΠ΅Π°ΠΊΡΠΈΠΈ Ρ ΡΠ΅ΠΌΠΏΠ΅ΡΠ°ΡΡΡΠΎΠΉ Π²ΡΡΠ΅ 38,6Β°Π‘. ΠΠ΅ΡΡΠ½ΡΠ΅ ΡΠ΅Π°ΠΊΡΠΈΠΈ ΠΎΡΠΌΠ΅ΡΠ°Π»ΠΈΡΡ Ρ 25,5%, ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΡΠ°ΡΠ΅ Ρ Π΄Π΅ΡΠ΅ΠΉ Ρ Π°Π»Π»Π΅ΡΠ³ΠΈΠ΅ΠΉ, ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ΠΌ Π¦ΠΠ‘ ΠΈ ΡΠ°ΡΡΠΎ Π±ΠΎΠ»Π΅ΡΡΠΈΡ
, ΡΠ΅ΠΌ Ρ Π·Π΄ΠΎΡΠΎΠ²ΡΡ
(7,8%), Π½ΠΎ Π½Π΅ ΠΏΡΠ΅Π²ΡΡΠ°Π»ΠΈ 3-5 ΡΠΌ. ΠΠΈ Ρ ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΡΠ΅Π±Π΅Π½ΠΊΠ° Π½Π΅ Π±ΡΠ»ΠΎ ΠΏΠΎΡΡΠ²Π°ΠΊΡΠΈΠ½Π°Π»ΡΠ½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ. ΠΡΠ΅Π½ΠΊΠ° ΡΠ΅Π°ΠΊΡΠΎΠ³Π΅Π½Π½ΠΎΡΡΠΈ Π²Π°ΠΊΡΠΈΠ½Ρ ΠΠ΅Π½ΡΠ°ΠΊΡΠΈΠΌ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΠ΅Ρ ΠΎ Π΅Π΅ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΈ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π°Π΅Ρ ΡΠ΅Π»Π΅ΡΠΎΠΎΠ±ΡΠ°Π·Π½ΠΎΡΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ 1 ΡΠ΅Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ² ΠΊΠΎΠΊΠ»ΡΡΠ°, Π΄ΠΈΡΡΠ΅ΡΠΈΠΈ, ΡΡΠΎΠ»Π±Π½ΡΠΊΠ°, ΠΏΠΎΠ»ΠΈΠΎΠΌΠΈΠ΅Π»ΠΈΡΠ° ΠΈ ΠΎΠ΄Π½ΠΎΠΊΡΠ°ΡΠ½ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ² Π³Π΅ΠΌΠΎΡΠΈΠ»ΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΡΠΈΠΏΠ° Π Π΄Π΅ΡΠ΅ΠΉ ΡΡΠ°ΡΡΠ΅ Π³ΠΎΠ΄Π° Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌ ΡΠΎΡΡΠΎΡΠ½ΠΈΠ΅ΠΌ Π·Π΄ΠΎΡΠΎΠ²ΡΡ
The estimation of safety booster vaccination children is more senior than 1,5 years against diphtheria, perussis, tetanus, poliomyelitis and Haemophilus influenzae type B with Pentaxim
Supervision over 200 children in the age of 18β42 months (64 healthy and 136 with allergic displays, defeats CNS, often ill, and also having in the anamnesis of reaction to previous introduction DTP or Infanriks), revaccination with Pentaxim. It is shown, that 77% from them had asymptomatic current, only in 1,5% of cases strong reactions with temperature above 38,6Β°Π‘ were observed. Local reactions were marked at 25,5%, essentially more often at children with an allergy, defeat CNS and often ill, than at healthy (7,8%), but did not one child was not adverse events. The estimation safety vaccines Pentaxim confirms expediency of application as 1 revaccination against perussis, diphtheria, tetanus, poliomyelitis and unitary vaccination against Haemophilus influenzae type B in children are more senior than year with a various state of health